The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

EuroIntervention 2013;9:308-315 published online ahead of print May 2013. DOI: 10.4244/EIJV9I3A52

1. MonashHeart, Clayton, Victoria, Australia; 2. Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium; 3. MedStar Health Research Institute, Washington, DC, USA; 4. Polyclinique Les Fleurs, Ollioules, France; 5. Middlemore Hospital

Aims: The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable poly

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation